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ABSTRACT   
Fosfomycin is an antibiotic widely used for the treatment and prevention of swine infections caused by 
resistant bacteria. The aim of this research was to study the penetration of fosfomycin in an in vitro 
model of intestinal cells (IPEC-J2 cells). Cells cultures were subjected to 580 µg/mL of calcium 
fosfomycin. Intracellular concentrations of the antibiotic were analyzed by HPLC MS/MS and they 
ranged from 23.48 to 45.81 µg/mL (Tmax: 4 h). Fosfomycin concentrations exceeded the MIC90 for the 
most important pathogens in swine intestinal infections (Escherichia coli: 0.50 µg/mL, Salmonella 
enterica subsp. Enterica: 4 µg/mL). Therefore, it is apparent that fosfomycin is an alternative for the 
treatment of intestinal infections in pigs. 
Keywords: Fosfomycin, in vitro, penetration, IPEC -2 cells, intestinal infections, pigs 
 
INTRODUCTION 
Swine industry provides one of the most important 
sources of animal protein, being pork industry the 
largest in production and consumption, followed 
by poultry meat and beef. In pig production, 
weaning is considered as a critical period for 
piglets. It is characterized by a decrease in food 
intake that leads to a status of under nutrition, 
affecting other aspects of animal physiology and 
metabolism (Dirkzwagera et al., 2005). During 
this period animals are more susceptible to 
infectious diseases (Nabuurs et al., 1993). The 
main sites of infection (biophase) of the pathogens 
responsible for these disorders are the interstitial 
and intracellular fluid. In this regard, it should be 
noted that most of enteric diseases are caused by 
intracellular organisms, such as Salmonella sp. 
(facultative intracellular) and Lawsonia 
intracellularis (obligate intracellular) (Pluske et 
al., 1996; Pedersen et al, 2008), although other 
microorganisms that are located at the 
extracellular level are also important, such as E. 
coli. 
Different antibiotics have been used for decades to 
reduce pathogen infection in pigs (irrational use). 
For this reason, many bacteria have become 
resistant to the most frequently used antimicrobials 
(Dirkzwagera et al., 2005; Mathew et al., 1998; 
Rood et al., 1985). Among the most recently used 
antibiotics is fosfomycin (cis-1,2-
epoxyphosphonic acid), an intensive production 
widely used antibiotic (Serrano, 2002) is a broad-
spectrum drug, structurally unrelated to other 
classes of antimicrobial agents. It inhibits cell wall 
synthesis as it interferes with peptidoglycan 
production at an earlier stage than beta-lactams or 
glycopeptide antibiotics (Gobernado, 2003; Kahan 
et al., 1974; Lin, 1976; Popovic et al., 2009). It has 
a low molecular weight (138.059 Da) and its 
chemical structure is similar to that of 
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phosphoenol-pyruvate. When compared with other 
antibiotics, fosfomycin has a broader in vitro 
spectrum of action than penicillin and semi-
synthetic cephalosporins (Mata et al., 1977), and 
cross-resistance has not been reported (Gobernado, 
2003). The use of fosfomycin in animals and 
humans has been proposed because of its low 
toxicity and potential efficacy (Gallego et al., 
1974), being also widely used in animal 
production due to its rapid effect, good tolerance 
and lack of side effects (Aramayona, 1997; 
Carramiñana, 2004). 
The pharmacokinetics of fosfomycin has been 
described in humans (Gallego et al., 1971; 
Damaso et al. 1990; Falagas et al., 2008), rabbits 
(Fernandez Lastra et al. 1986, 1987), broilers 
(Aramayona et al., 1997, Soraci et al. 2011), cattle 
(Sumano et al., 2007), horses (Zozaya et al., 
2008), dogs (Gutiérrez et al., 2008) and pigs 
(Soraci et al, 2011, Pérez et al., 2012). Its chemical 
structure supports different salts: sodium, calcium 
and tromethamine (Perez-Rodriguez and Chavez 
Hernandez Velasco, 1997; Serrano, 2002). This is 
due to its acidic nature that allows the rapid 
formation of salts. The fosfomycin-calcium salt 
formulation is used orally, whereas the more 
water-soluble disodium salt can be used 
intravenously. Fosfomycin-tromethamine salt is 
highly hydro-soluble and offers a good oral 
bioavailability in humans (Borsa et al., 1988; Patel 
et al., 1997; Popovic et al., 2009). Perez et al. 
(2011, 2012) have established a fosfomycin 
withdrawal period of 3 days for broiler chicken 
muscle, liver and kidney and of 3 days after oral 
administration and 2 days after intramuscular 
administration in pig tissues. 
It has been demonstrated that, besides being a 
bacterial inhibitor, fosfomycin has other properties 
such as, inhibition of bacterial adhesion to 
epithelial cells, penetration of wells in biofilms of 
exo-polysaccharide and protection against 
nephrotoxicity caused by drugs such as, cisplatin, 
cyclosporine, aminoglycosides, vancomycin, 
teicoplanin, amphotericin B and polymyxin 
(Gobernado, 2003). Martínez et al. (2011) 
demonstrated fosfomycin has a protective effect 
on HEp-2 cells when they are incubated with the 
mycotoxin deoxinivalenol. Morikawa et al. (1993) 
and Honda et al. (1998) have shown that 
fosfomycin has immunomodulatory effect on 
lymphocytes. Similarly, Krause et al. (2001) 
studied the effect of fosfomycin on neutrophil 
function and showed that destruction of 
microorganisms is increased when incubated with 
this antibiotic. 
Fosfomycin exhibits a time dependent killing, so it 
kills bacteria when its concentrations remain 
constantly above the Minimum Inhibitory 
Concentration (MIC) (Aliabadi and Lees, 1997; 
Toutain et al., 2002). In this regard, for an 
antibiotic to be effective against relevant 
pathogens, it is essential to reach concentrations 
higher than the minimum inhibitory concentration 
(MIC) at the site of action (Nix et al., 1991; 
Schentag and Ballow, 1991; Toutain et al., 2002). 
Fosfomycin is indicated for the treatment of a 
variety of porcine bacterial pathogens 
(Haemophilus parasuis, Streptococcus suis, 
Pasteurella multocida, Bordetella bronchiseptica, 
Staphylococcus hyicus, Escherichia coli, 
Salmonella enterica) associated with stress and/or 
several viral diseases (Martineau, 1997) and it 
MIC90 for most of the important pathogens in 
swine production has been established in 0.25-4 
µg/mL (Fernández et al., 1995, Sumano et al., 
2007, Ibar et al., 2009). In this regard, Pérez et al. 
(2012), have demonstrated that fosfomycin is an 
alternative for the treatment of intracellular 
respiratory infections in pigs, because it penetrates 
in HEP-2 cells and reaches concentrations that 
exceed the MIC90 for the most important 
pathogens in swine respiratory infections.  
Although fosfomycin is widely used in clinical 
practice in the pork industry, its use in pigs is 
given on the basis of its potential clinical efficacy. 
However, there are no studies showing that this 
antibiotic reaches adequate concentrations in the 
biophase where the most important pathogens 
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operate. It was hypothesized that the antibiotic 
reaches concentrations above the MIC90 for most 
of the enteric microorganisms which are relevant 
in swine production systems. According to this 
background, the aim of this work was to determine 
fosfomycin concentration in the intracellular fluid 
of IPEC-J2 cells, as a model of fosfomycin 
penetration into intestinal cells and to determine 
the relationship between intracellular and serum 
fosfomycin concentrations in weaning piglets.  
 
MATERIALS AND METHODS 
This work was performed at the Laboratory of 
Toxicology of the Faculty of Veterinary Sciences, 
Tandil Veterinary Research Center, UNICEN, 
Tandil, Buenos Aires, Argentina. 
Antibiotic 
Calcium fosfomycin (98.9% of purity) was from 
Bedson Laboratory, Pilar, Buenos Aires, 
Argentina. 
We use a dose of 580 µg/mL, which was estimated 
considering a therapeutic dose of 30 mg/kg body 
weight (b.w.) of calcium fosfomycin for pigs, an 
average post-weaning piglet b.w. of 15 kg, the 
intestinal volume where the antibiotic is dissolved 
(622 mL) (Ruckebusch, 1981) and a 
bioavailability (F%) of 20 (Pérez et al, 2012, 
unpublished data), so the 80 % of the drug remains 
in the gut. Stock solution of fosfomycin calcium 
salt was prepared in physiological saline solution 
(PSS).  
Cell line 
 For these experiments, IPEC-J2 cells were used. 
These cells were kindly provided by Dr. Anthony 
Blikslager (North Carolina State University, 
Raleigh, NC). IPEC-J2 is a non-transformed 
columnar epithelial cell line, from the mid-
jejunum of a neonatal piglet. They were originated 
in 1989, by Helen Berschneider, at the University 
of North Carolina (Brosnahan and Brown, 
2012).Given the high homology in porcine and 
human intestinal structure and function, and 
presumably in enterocytes as well (Geens and 
Niewold, 2011; Brosnahan and Brown, 2012), 
studies performed with IPEC-J2 cells may provide 
valuable insights on the penetration of antibiotics 
in the human intestinal mucosa.  
Cells were cultured in Dulbecco’s modiﬁed Eagle 
medium: nutrient mixture F-12 (Ham) (1:1) with 
GlutaMAX™-I (DMEM/F12) (Invitrogen TM Life 
Technologies, Carlsbad, CA, USA), supplemented 
with 20% fetal bovine serum, 1% insulin-
transferring-selenium supplements (Invitrogen), 
1% epidermal growth factor (Invitrogen) and 1% 
penicillin-streptomycin (penicillin 10,000 U/ml 
and streptomycin 100 mg/ml; Invitrogen) in a 
humidiﬁed atmosphere of 5% CO2 at 37ºC. IPEC-
J2 cells were seeded into 24-well plates at a 
concentration of 1.2 x 10
-6
/ml. Cells in a conﬂuent 
monolayer were used in all experiments. The cells 
were maintained in an atmosphere of 5% CO2 at 
37ºC for 24 h.  
Cell viability 
Cell concentration and viability were determined 
by trypan blue exclusion assay after 24 h of 
incubation of IPEC-J2 cells with fosfomycin.  
Experimental design 
The culture medium was removed and cells 
cultures were washed with PSS to eliminate 
residual PBS, since phosphates of the buffer might 
interfere with the detection of fosfomycin by 
HPLC-MS/MS. Cells were incubated from 5 
minutes to 24 hours at 37 º C and 5% CO2, 
depending on the experiment, a-) IPEC-J2 cells 
were incubated with 1 mL of PSS, in absence of 
fosfomycin (negative control); b-) Cell cultures 
were incubated with 1 mL of the 580 µg/mL stock 
solution of calcium fosfomycin. The results were 
corroborated by six-replicates. 
Cell cultures were observed under an inverted 
microscope at 40X to determine if the monolayer 
was intact and cell detachment, cytoplasmic ‘dots’ 
(sign of intoxication) and loss of cell membrane 
were not present. In any case, cells were not 
affected during the incubation period. 
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Determination of fosfomycin concentrations in 
IPEC-J2 cells 
After each incubation time (15, 30, 45 min, 1, 2, 3, 
4, 6, 8, 12, 18 and 24 h, the supernatant was 
collected and each well containing IPEC-J2 cells 
was washed twice with HPLC water. Supernatants 
were centrifuged at 3500 rpm for 6 minutes to 
obtain the extracellular fosfomycin. Pellet 
(sloughed cells) was restored to the corresponding 
well. After the addition of 2 mL of HPLC water to 
the wells, culture plates were sealed and sonicated 
for 30 min to break the cells and release 
fosfomycin to the HPLC water. Then, the content 
of each well was centrifuged at 10,000 rpm at 4 º 
C. One mL was filtered through nylon filters of 
0.22 um, placed in vials, and intra and 
extracellular concentrations of fosfomycin were 
determined by HPLC-MS / MS.  
To estimate the influence of IPEC-J2 cells 
intracellular water on fosfomycin intracellular 
concentrations, we based on Kiem and Shentag 
(2008) work .We have into account the IPEC-J2 
cell count in a well plate (1.2 x 10
6
 cells) and the 
mean cell volume (2.75 x 10
-6
). Therefore, 
processed data obtained from Xcalibur software 
were re-calculated considering the intracellular 
volume of water. The degree of penetration of 
fosfomycin into IPEC-J2 cells was determined by 
comparing the AUC0–t of IPEC-J2 cells with the 
AUC0–t of serum. 
Instruments 
The HPLC-MS/MS system was from Thermo 
Electron Corporation (San Jose, CA, USA), 
consisting of a Finnigan Surveyor auto sampler, a 
Finnigan Surveyor MS quaternary pump. The 
detector was a Thermo Quantum Discovery Max 
triple quadrupole mass spectrometer, equipped 
with a ESI source. Nitrogen used as nebulizer and 
sheath gas was obtained through a nitrogen 
generator from Peak Scientific Ltd. (Inchinnan, 
Scotland). Data processing was done using 
Xcalibur software, also from Thermo.  
 
 
Mass Spectrometer conditions 
The mass spectrometer was operated in negative 
ionization mode. The tuning parameters were 
optimized with 10 µg/mL individual aqueous 
solutions of fosfomycin directly infused in the ion 
source by means of a syringe pump at 10 µl/min, 
with influence of mobile phase delivered from the 
LC pump through a T connection to give the 
corresponding chromatographic flow rate. The 
spray voltage was set to -3800 eV, the capillary 
temperature was 350 ºC, and argon 99,999% 
purity was used for collision induced dissociation 
(CID) at 1.6 m Torr in the collision cell. Source 
CID energy was set to -8eV. Fosfomycin detection 
and quantification were achieved by single 
reaction monitoring of transitions m/z 137 → 79 
with an optimized collision energy of 25. 
 
CHROMATOGRAPHIC CONDITIONS 
Separation was achieved on a Phenomenex CN 
(cyano) stationary phase, 75 mm x 4.6 i.d., 5 µm 
column. The mobile phase consisted on 
acetonitrile: water  (20:80), working in isocratic 
mode, at a flow rate of 100 µl/min. The column 
was maintained at 30 ºC, while the samples in the 
auto sampler were at 10 ºC. Sample injection 
volume was 20µl, chromatographic run time was 8 
min and fosfomycin retention time was 6 min. 
 
Statistical analysis 
Results were analyzed by ANOVA, using InStat3 
software. 
 
RESULTS 
The viability of the cells incubated with 
fosfomycin after 24 h of incubation was 100%. 
The concentrations of intracellular antibiotic in the 
wells incubated with 580 ppm calcium fosfomycin 
ranged between 23.48 and 45.81 µg/ml (Table 1). 
Figure 1 shows fosfomycin mean intracellular 
concentrations in IPEC-J2 cells. The Tmax, moment 
where fosfomycin reached its maximal 
intracellular concentration, was 4 h. After this 
time, the concentration of intracellular antibiotic 
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started to decrease until it reached concentrations 
of 23.48 µg/ml at 24 h of incubation.  
Only a 7.89 % of the administrated dose was able 
to enter the IPEC-J2 cells, remaining most of the 
antibiotic in the extracellular fluid.  
Insert Table 1 
Fosfomycin AUC in serum, Cmax and Tmax in 
weaning piglets were determined by Soraci et al. 
(2011). Fosfomycin AUC0–t after an oral dose of 
calcium fosfomycin was 39.6 µg-h/mL. 
Fosfomycin AUC0–t after the incubation with 580 
µg/mL of calcium fosfomycin was 729.60. The 
ratio of fosfomycin AUC in IPEC-J2 cells 
compared to AUC in serum (AUCIPEC-J2 / 
AUCserum) was 18.42. The Cmax was 3.60 µg/mL 
for the calcium salt orally administered, and 45.81 
µg/mL for the 580 µg/mL dose of calcium 
fosfomycin in IPEC-J2 cells. These concentrations 
were achieved at different times. Tmax were: 3 h 
(fosfomycin calcium salt in serum) and 4 h (580 
µg/mL calcium fosfomycin dose in IPEC-J2 cells). 
Table 2 shows some pharmacokinetics parameters 
of fosfomycin in serum (after a after a single oral 
dose of 30 mg/kg b.w.) and in IPEC-J2 cells (after 
incubation with calcium fosfomycin; 580 µg/mL). 
Insert Table 2 
 
DISCUSSION 
For many clinically relevant pig enteric 
pathologies, intestinal cells represent a major site 
of infection by intracellular pathogens (biophase) 
(Schentag, 1990; Toutain et al., 2002; Ross, 2006; 
Došen et al., 2007). We decided to use IPEC-J2 
cells as an in vitro model to estimate intracellular 
fosfomycin concentrations in intestinal cells. The 
capacity of certain antibiotics to penetrate cell 
membranes represents an important pre-requisite 
for their in vivo efficacy against intracellular 
bacteria (Mandell, 1973; Johnson et al., 1980; 
Yourtee and Root, 1982; Jacobs and Wilson, 1983; 
Höger et al., 1985).  
Antibiotics with high lipid solubility are able to 
penetrate cell membranes (Mandell, 1973; Johnson 
et al., 1980). However, fosfomycin is known to be 
a hydrophilic drug and, therefore, passive 
transmembrane diffusion is an improbable 
explanation for its uptake (Höger et al., 1985). 
Apparently, passive transport through the bacterial 
cell membrane is not a likely mechanism. 
Nevertheless, intracellular penetration of a small 
quantity of the drug by this mechanism cannot be 
rejected. The presence of the antibiotic inside the 
cells might be explained by active diffusion of 
transmembrane. Milagre et al. (2011) 
demonstrated that fosfomycin is uptaken by a 
proteic transport system. Kahan et al. (1974), 
shown the existence of two different active 
transport mechanisms for fosfomycin. In some 
bacteria, the drug is incorporated via the sn-
glycero-3-phosphate transport system. Under 
certain conditions, the glucosa-6-phosphate 
system, which can be externally induced, may also 
be used. We hypothesized that a similar 
mechanism takes place in animal cells, so it is 
possible that a similar active transport mechanism 
for fosfomycin is present in the enterocytes, as 
described for bacteria.  
In the present study, we found that the 
concentrations of fosfomycin were significantly 
higher in IPEC-J2 cells than in serum, at all 
sampling times. Bacteria may survive within cells 
and remain unaffected by those antimicrobial 
agents which are unable to reach the intracellular 
space. There are several antibiotics with known 
intracellular accumulation and efficacy against 
intracellular pathogens. However, the clinical 
applicability might be limited by their adverse 
effects on important neutrophil functions. Such 
inhibitory actions of antibiotics on host defense 
mechanisms might be critical in 
immunocompromised hosts (Woodruff et al., 
1977). This undesirable effect is not present after 
fosfomycin administration (Gobernado, 2003) and, 
on the contrary, Morikawa et al. (1993) and Honda 
et al. (1998) have shown it has immunomodulatory 
effect on lymphocytes. Krause et al. (2001) have 
demonstrated an increased power of destruction of 
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microorganisms when neutrophils are incubated in 
the presence of fosfomycin. 
Besides all this, an antibiotic taken up 
intracellularly can only be clinically useful if it 
retains its bactericidal activity. Many infectious 
diseases are caused by facultative organisms that 
are able to survive within cells. The intracellular 
location of these microorganisms protects them 
from the host defense mechanisms and from 
antibiotics with poor penetration into phagocytic 
cells (Briones et al., 2008). In swine production, 
the intracellular and interstitial fluids are the 
biophase of Mycoplasma hyopneumoniae, 
Bordetella bronchisceptica, Salmonella 
cholerasuis, Salmonella enterica, Pasteurella 
multocida, Streptococcus sp. and Lawsonia 
intracellularis. These bacteria would be killed as 
soon as the antibiotic reaches a bactericidal 
concentration within the cell (Höger et al., 1985). 
So, as described, the choice of an antibiotic is 
dependent on its direct antimicrobial activity. 
Generally, this property is detected in vitro by 
determination of the MIC (Herbert, 2002). A 
fosfomycin MIC90 of 0.25-4 µg/mL (Fernández et 
al., 1995, Ibar et al. 2009) has been determined for 
the most important pathogens in swine production. 
Our studies in HEP-2 cells with three different 
doses of fosfomycin demonstrated the penetration 
of the antibiotic into the cells (Pérez et. al., 2012), 
but the amounts were lower than in IPEC-J2 cells. 
We found that the intracellular penetration was 
around 7.89 % of the incubation dose and 
concentrations were always higher than the MIC90 
for the most important enteric pathogens in swine 
production. When compared with the percentage 
of the antibiotic that penetrates in HEP-2 cells, it 
was also higher in the intestinal cells (7.89 vs. 
0.25-1.42). 
Studies of PK/PD of several antibiotics have 
demonstrated the importance of measuring the 
concentrations of antibiotics at the infection sites, 
taking into account that the distribution of the drug 
may vary according to the tissues (Nix et al, 1991; 
Schentag and Ballow, 1991; Toutain et al, 2002).  
The penetration of drugs into various tissues is 
best described by the use of the AUC (area under 
the curve), which responds to variations in 
concentration with time (Schentag and Ballow, 
1991; Kiem and Schentag, 2008). The comparative 
AUCIPEC-J2 vs. AUCserum was considered significant 
(p <0.05). Orally administered calcium fosfomycin 
has a low bioavailability (20%) (Pérez et al., 2012, 
unpublished data), so the 80 % of the drug reaches 
de gut and is in conditions to penetrate into the 
enterocites. Tmax is reached 1 h later in IPEC-J2 
than in serum (4 h vs. 3 h). 
When the time period exceeding the MIC for the 
relevant pathogen (t > MIC) is maximized (%T > 
MIC), optimal bacterial killing by fosfomycin will 
be achieved (Sumano et al., 2007; Gutierrez et al., 
2009; Popovic et al., 2010). In addition, an 
effective bacterial killing can be expected when 
the MIC for the pathogen is covered for at least 
60-70% of the dosing interval (McKellar et al., 
2004). Salmonella enterica is considered an 
important agent in enteric diseases of weaning 
piglets. Fosfomycin MIC90 for this pathogen has 
been determined at 4 µg/ml, and bacteria have 
demonstrated to be 100% sensitive to this 
antibiotic, with no resistance (Ibar et al., 2009). In 
the present study, fosfomycin concentrations in 
IPEC-J2 cells were always above the MIC90 for 
Salmonella enterica up to 24 h and at the 
therapeutic dose assayed. 
 
CONCLUSIONS 
Fosfomycin MIC90 is 0.25-4 µg/mL for the most 
important pathogens in swine production. As 
demonstrated in this study, concentrations 
achieved at the cellular level are remarkably 
higher. These findings make fosfomycin an 
excellent alternative for the treatment of enteric 
intracellular infections in pigs, and taking into 
account the great amount of the antibiotic which 
remains in the gut, it is a good drug to treat other 
pathogens at the extracellular level. To further 
corroborate our in vitro studies, additional 
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experiments should be carried out in pigs infected 
with enteric pathogens. 
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Figure 1: Mean intracellular concentrations of calcium fosfomycin in IPEC-J2 cells after the 
incubation with a dose of 580 µg/mL. 
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Figure 2: Mean concentrations of calcium fosfomycin in serum (30 mg/kg b.w.) vs. mean 
intracellular concentrations of calcium fosfomycin in IPEC-J2 cells (580 µg/mL). 
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Table 1: Penetration of calcium fosfomycin into IPEC-J2 cells (Data are means from experiments 
performed in sixtuplicate ± SD) 
 
Time Fosfomycin concentration 
(µg/ml) in IPEC J2 cells 
15 min 27,81 ± 2,71 
30 min 32,24 ± 4,89 
1 h 34,25 ± 5,88  
2 h 37,44 ± 8,45 
3 h 38,53 ± 7,67 
4 h 45,81± 3,84 
6 h 36,09 ± 1,59 
8 h 31,79 ± 4,37 
12 h 28,86 ± 5,09 
18 h 26,10 ± 4,51 
24 h 23,48 ± 8,64 
 
Table 2: Calcium fosfomycin pharmacokinetics parameters in serum and IPEC-J2 cells 
 
Parameters Serum IPEC-J2 cells 
 Calcium Fosfomycin Calcium Fosfomycin 
30 mg/kg b.w. 580 µg/mL 
AUC0-t 
µg.h/mL 
39.60 729.60 
Cmax µg/mL 3.60 45.81 
Tmax (h) 3.00 4.00 
 
